The use of biological strategies to treat cartilage disorders has become popular in the past 20 years: The real explosion occurred with the introduction of platelet-rich plasma into clinical practice, and from that moment onward, a huge number of "biologic products" invaded the market, taking advantage of a confusing regulatory environment. Such an abundance is actually not backed up by solid clinical data to support the safety and efficacy of these products. This "gold rush" for biologics could soon produce dangerous effects if neglected by physicians and competent authorities.
|Titolo:||Editorial Commentary: Biologic Products for Cartilage Regeneration—Time to Redefine the Rules of the Game?|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||1.1 Articolo in rivista|